Search research articles
Contact Us
Filters
Showing results (131-140 of 152) with videos related to
Page
of 16
Sort By:
Blood
|
September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
Richard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
Dennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2016
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Priya Chudasama, Marcus Renner, Melanie Straub, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography
Thomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 1, 2024
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
Ronald Boellaard, Irène Buvat, Christophe Nioche, et al.
Blood
|
October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 9, 2023
How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation
Valentina Ambrosini, Sofia Carrilho Vaz, Niloefar Ahmadi Bidakhvidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group
Michael Fuchs, Helen Goergen, Carsten Kobe, et al.
Lancet (London, England)
|
April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 152) with videos related to
Sort By:
Page
of 16
Blood
|
September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
Richard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
Dennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2016
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Priya Chudasama, Marcus Renner, Melanie Straub, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography
Thomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 1, 2024
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
Ronald Boellaard, Irène Buvat, Christophe Nioche, et al.
Blood
|
October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 9, 2023
How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation
Valentina Ambrosini, Sofia Carrilho Vaz, Niloefar Ahmadi Bidakhvidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group
Michael Fuchs, Helen Goergen, Carsten Kobe, et al.
Lancet (London, England)
|
April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Page
of 16